Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Más filtros

Base de datos
Intervalo de año de publicación
J Cardiovasc Pharmacol ; 66(5): 497-503, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26248276


Obesity is a major global health concern and is associated with hypertension. However, there is a lack of studies evaluating the effectiveness of valsartan/amlodipine single-pill combination in Chinese hypertensive patients with excess body weight uncontrolled by monotherapy. To evaluate this effectiveness and its association with obese categories, we performed a prespecified subanalysis and a post hoc analysis of patients from China status II study. In this subanalysis, 11,289 and 11,182 patients stratified by body mass index (BMI) and waist circumference (WC), respectively, were included. Significant mean sitting systolic and diastolic blood pressure (BP) reductions from baseline were observed at week 8 across all BMI and WC subgroups (P < 0.001). The percentages of patients achieving BP control were 65.2%, 62.8%, and 64.5% (men 64.5% and women 64.4%) in the overweight, obesity, and abdominal obesity subgroups, respectively. The positive association between BP control and obese categories could only be found in subgroups stratified by BMI other than WC. Our study demonstrated the effectiveness of valsartan/amlodipine single-pill combination in Chinese hypertensive patients with excess body weight uncontrolled by monotherapy, and its effectiveness was better associated with BMI than WC.

Combinación Amlodipino y Valsartán/uso terapéutico , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Bloqueadores de los Canales de Calcio/uso terapéutico , Hipertensión/tratamiento farmacológico , Sobrepeso/complicaciones , Adolescente , Adulto , Anciano , Combinación Amlodipino y Valsartán/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Índice de Masa Corporal , Bloqueadores de los Canales de Calcio/efectos adversos , China , Femenino , Humanos , Hipertensión/complicaciones , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Sobrepeso/diagnóstico , Sobrepeso/fisiopatología , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento , Circunferencia de la Cintura , Adulto Joven
Biochem Biophys Res Commun ; 450(1): 500-6, 2014 Jul 18.
Artículo en Inglés | MEDLINE | ID: mdl-24928385


Mitofusin 2 (Mfn2) inhibits atherosclerotic plaque formation, but the underlying mechanism remains elusive. This study aims to reveal how Mfn2 functions in the atherosclerosis. Mfn2 expression was found to be significantly reduced in arterial atherosclerotic lesions of both mice and human compared with healthy counterparts. Here, we observed that Mfn2 increased cellular cholesterol transporter expression in macrophages by upregulating peroxisome proliferator-activated receptor-γ, an effect achieved at least partially by inhibiting extracellular signal-regulated kinase1/2 (ERK1/2) and p38 mitogen-activated protein kinases (MAPKs) pathway. These findings provide insights into potential mechanisms of Mfn2-mediated alterations in cholesterol transporter expression, which may have significant implications for the treatment of atherosclerotic heart disease.

GTP Fosfohidrolasas/metabolismo , Metabolismo de los Lípidos/fisiología , Sistema de Señalización de MAP Quinasas/fisiología , Macrófagos/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Proteínas Mitocondriales/metabolismo , PPAR gamma/metabolismo , Línea Celular , Regulación de la Expresión Génica/fisiología , Humanos